Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 501–600 of 1,000
Approach to the Patient: Normocalcemic Primary Hyperparathyroidism
Liu, Y., Gregory, N. S., Andreopoulou, P., Kashyap, S. R., & Cusano, N. E. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae659 · Cited by 26
Nakamura, Y., Suzuki, T., & Kato, H. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0371-y · Cited by 26
Denosumab for cancer-related bone loss
Dell’Aquila, E., Armento, G., Iuliani, M., Simonetti, S., D’Onofrio, L., Zeppola, T., Madaudo, C., Russano, M., Citarella, F., Ribelli, G., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1814731 · Cited by 26
Therapeutic effect of aqueous extract from Ecliptae herba on bone metabolism of ovariectomized rats
Zhang, Z., Bai, D., Liu, M.-J., Li, Y., Pan, J., Liu, H., Wang, W., Xiang, L., Xiao, G. G., & Ju, D. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318265e7dd · Cited by 26
The role and efficacy of denosumab in the treatment of osteoporosis: an update
Charopoulos, I., Orme, S. M., & Giannoudis, P. V. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.516249 · Cited by 29
Antiresorptive therapies in oncology and their effects on cancer progression
Bundred, N. J. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.002 · Cited by 26
Clinical applications of RANK‐ligand inhibition
Romas, E. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01732.x · Cited by 31
Emerging drugs for postmenopausal osteoporosis
Lewiecki, E. M. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902766813 · Cited by 28
Self-citationEmerging pharmacologic therapies for osteoporosis
Grey, A. B. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.3.493 · Cited by 27
Therapeutic Targets of the TNF Superfamily
Grewal, I. S. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-89520-8 · Cited by 29
Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review
Wang, D., Tang, X., Shi, Q., Wang, R., Ji, T., Tang, X., & Guo, W. (2023) · Translational Pediatrics · doi:10.21037/tp-22-276 · Cited by 33
Tokuyama, N., Hirose, J., Omata, Y., Yasui, T., Izawa, N., Matsumoto, T., Masuda, H., Ohmiya, T., Yasuda, H., Saito, T., et al. (2015) · Bone Reports · doi:10.1016/j.bonr.2014.12.002 · Cited by 26
Emerging therapeutic targets for osteoporosis
Gennari, L., Merlotti, D., Falchetti, A., Eller-Vainicher, C., Cosso, R., & Chiodini, I. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1726889 · Cited by 25
Clarke, B. L. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.04.005 · Cited by 25
So, H., Cheng, I. T., Lau, S.-L., Chow, E., Lam, T. T., Hung, V. W.-Y., Li, E. K., Griffith, J. F., Lee, V. W. Y., Shi, L., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-219846 · Cited by 24
Bone turnover assessment: a good surrogate marker?
Dreyer, P., & Vieira, J. G. H. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200003 · Cited by 27
Interaction between the immune system and bone metabolism: an emerging field of osteoimmunology
Takayanagi, H. (2007) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.83.136 · Cited by 24
Karopoulou, E., Augoulea, A., Triantafyllopoulos, I. Κ., Rizos, D., Armeni, E., Pliatsika, P., Tsoltos, N., Tournis, S., Tsakonas, E., Antoniou, A., et al. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.03.136 · Cited by 25
Long-term follow-up in osteogenesis imperfecta type VI
Trejo, P., Palomo, T., Montpetit, K., Fassier, F. R., Sato, A., Glorieux, F. H., & Rauch, F. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4141-x · Cited by 24
Fontalis, A., Kenanidis, E. I., Prousali, E., Potoupnis, M. E., & Tsiridis, E. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1430764 · Cited by 24
Ubiquitin-mediated signalling and Paget's disease of bone
Layfield, R., & Shaw, B. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s5 · Cited by 26
Parathyroid hormone receptor agonists in the management of osteoporosis
Fuggle, N. R., Rizzoli, R., Beaudart, C., Cortet, B., Curtis, E. M., Hiligsmann, M., Kaufman, J., Veronese, N., Albergaria, B. H., Al‐Daghri, N. M., et al. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01287-w · Cited by 29
Self-citationFuture of bisphosphonates and denosumab for men with advanced prostate cancer
Iranikhah, M., Stricker, S., & Freeman, M. K. (2014) · Cancer Management and Research · doi:10.2147/cmar.s40151 · Cited by 23
Kang, T., Park, S.-Y., Lee, S. H., Park, J. H., & Suh, S. W. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e68 · Cited by 23
Jeka, S., Dokoupilová, E., Kivitz, A., Żuchowski, P., Vogg, B., Krivtsova, N., Sekhar, S., Banerjee, S., Schwebig, A., Poetzl, J., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae016 · Cited by 23
Self-citationAppropriate models for novel osteoporosis drug discovery and future perspectives
Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1080685 · Cited by 23
Developments in the scientific understanding of osteoporosis
Lane, N. E., & Yao, W. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2656 · Cited by 32
Seeman, E. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.261 · Cited by 23
Westenfeld, R., Ketteler, M., & Brandenburg, V. M. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl245 · Cited by 28
Cairoli, E., Eller-Vainicher, C., & Chiodini, I. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s75681 · Cited by 23
Novel therapies in benign and malignant bone diseases
Rachner, T. D., Hadji, P., & Hofbauer, L. C. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.02.005 · Cited by 25
Lloyd, S. A. J., Travis, N. D., Lü, T., & Bateman, T. A. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00632.2007 · Cited by 27
Evaluating and mitigating fracture risk in established rheumatoid arthritis
Mullen, M. B., & Saag, K. G. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.09.005 · Cited by 27
Bone-seeking agents for the treatment of bone disorders
Cawthray, J. F., Wasan, E. K., & Wasan, K. M. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0394-3 · Cited by 23
Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
Xie, J., Li, S., Xiao, L., Ouyang, G., Zheng, L., Gu, Y., Gao, C., & Han, X.-W. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1492-3 · Cited by 25
Wu, C., Hung, W., Chang, I., Tsai, T., Chang, Y., McCloskey, E. V., Watts, N. B., McClung, M. R., Huang, C., Chen, C., et al. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100729 · Cited by 25
Self-citationTreatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
New anti-resorptives and antibody mediated anti-resorptive therapy
Farrier, A. J., Franco, L. C. S., Shoaib, A., Gulati, V., Johnson, N. A., Uzoigwe, C. E., & Choudhury, M. (2016) · The Bone & Joint Journal · doi:10.1302/0301-620x.98b2.36161 · Cited by 22
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
Teramachi, J., Miki, H., Nakamura, S., Hiasa, M., Harada, T., & Abe, M. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01403-4 · Cited by 23
Ting, M., Huynh, B. H., Woldu, H. G., El-Hussein, I. G., & Suzuki, J. B. (2023) · Journal of Oral Implantology · doi:10.1563/aaid-joi-d-21-00160 · Cited by 25
Takahashi, T., Tonami, Y., Tachibana, M., Nomura, M., Shimada, T., Aburada, M., & Kobayashi, S. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00445 · Cited by 22
The Role of Autoantibodies in Bone Metabolism and Bone Loss
Hauser, B., & Harre, U. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0370-4 · Cited by 22
Rodríguez, E. G., Stoll, D., & Lamy, O. (2018) · Case Reports in Rheumatology · doi:10.1155/2018/5432751 · Cited by 22
Epigenetic therapies of osteoporosis
de Nigris, F., Ruosi, C., Colella, G., & Napoli, C. (2020) · Bone · doi:10.1016/j.bone.2020.115680 · Cited by 23
Volumetric Bone Mineral Density in Cementless Total Hip Arthroplasty in Postmenopausal Women
Aro, H. T., Engelke, K., Mattila, K. T., & Löyttyniemi, E. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.01614 · Cited by 22
A Case of SAPHO Syndrome with Endodontic Implications and Treatment with Biologic Drugs
Cotti, E., Careddu, R., Schirru, E., Marongiu, S., Barca, M. P., Manconi, P. E., & Mercuro, G. (2015) · Journal of Endodontics · doi:10.1016/j.joen.2015.04.005 · Cited by 22
RANK, RANKL and OPG Expression in Breast Cancer – Influence on Osseous Metastasis
Ney, J. T., Fehm, T. N., Juhasz-Böess, I., & Solomayer, E. (2012) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0031-1298276 · Cited by 26
Assessing Fracture Risk and Effects of Osteoporosis Drugs: Bone Mineral Density and Beyond
Davison, K. S., Kendler, D. L., Ammann, P., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., McClung, M. R., Olszynski, W. P., et al. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.018 · Cited by 24
Self-citationPharmacologic Augmentation of Implant Fixation in Osteopenic Bone
Ross, R. D., Hamilton, J. L., Wilson, B. M., Sumner, D. R., & Virdi, A. S. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0182-z · Cited by 22
Nakamura, Y., Suzuki, T., Yoshida, T., Yamazaki, H., & Kato, H. (2017) · Nutrients · doi:10.3390/nu9050428 · Cited by 22
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., & Bauer, D. C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00067-4 · Cited by 32
New and emerging treatments for osteoporosis
Maricic, M. J. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328172dc1a · Cited by 22
Matsushita, Y., Hayashida, S., Morishita, K., SAKAMOTO, H., Naruse, T., Sakamoto, Y., Yamada, S., Yanamoto, S., Fujita, S., Ikeda, T., et al. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.696 · Cited by 24
Campisi, G., Mauceri, R., Bertoldo, F., Fusco, V., & Bedogni, A. (2021) · Head & Face Medicine · doi:10.1186/s13005-021-00280-4 · Cited by 21
Yang, L., Zhang, H., Zhang, X., Tang, Y., Wu, Z., Wang, Y., Hai, H., Fu, X., Liu, J., Hogendoorn, P. C. W., et al. (2021) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2021.151882 · Cited by 21
Inter-daily variability in body composition among young men
Kutáč, P. (2015) · Journal of PHYSIOLOGICAL ANTHROPOLOGY · doi:10.1186/s40101-015-0070-6 · Cited by 21
Pharmacological Mechanisms of Therapeutics
Hanley, D. A., Watson, P. H., Hodsman, A. B., & Dempster, D. W. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00085-9 · Cited by 21
Chavassieux, P., Portero-Muzy, N., Roux, J. P., Horlait, S., Dempster, D. W., Wang, A., Wagman, R. B., & Chapurlat, R. D. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3631 · Cited by 21
Investigating the Use of Denosumab in the Treatment of Acute Charcot Neuroarthropathy
Shofler, D. W., Hamedani, E., Seun, J., Sathananthan, A., Katsaros, E., Liggan, L., Kang, S., & Pham, C. (2020) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2020.09.018 · Cited by 21
A Systems Approach to Understanding Bone Cell Interactions in Health and Disease
Pivonka, P., Buenzli, P. R., & Dunst, C. R. (2012) · InTech eBooks · doi:10.5772/51149 · Cited by 21
Burgess, J. R., & Raven, E. L. (2009) · Advances in inorganic chemistry · doi:10.1016/s0898-8838(09)00205-0 · Cited by 22
Osteopenia and osteoporosis in people living with HIV: multiprofessional approach
Lima, A. L. L. M., de Oliveira, P. R. D., Plapler, P. G., Marcolino, F. M. D. A., Meirelles, E. D. S., Sugawara, A., Gobbi, R. G., Santos, A. L. G. D., & Camanho, G. L. (2011) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s6617 · Cited by 26
Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3–4, 2007
Lewiecki, E. M., Bilezikian, J. P., Cooper, C. C., Hochberg, M. C., Luckey, M. M., Maricic, M. J., & Miller, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.017 · Cited by 21
Self-citationThe balance between risks and benefits: Long-term use of aromatase inhibitors
Perez, E. A. (2006) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2006.06.003 · Cited by 21
The remodeling transient and the calcium economy
Aloia, J. F., Talwar, S. A., Pollack, S. Z., & Yeh, J. K. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0542-6 · Cited by 21
Geers, J., Bing, R., Pawade, T., Doris, M. K., Daghem, M., Fletcher, A. J., White, A. C., Forsyth, L., Evans, E., Kwieciński, J., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032571 · Cited by 20
Li, M., Ge, Z., Zhang, B., Sun, L., Wang, Z., Zou, T., & Chen, Q. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01447-7 · Cited by 20
Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer
Milat, F., Goh, S. P., Gani, L. U., Suriadi, C., Gillespie, M. T., Fuller, P. J., Teede, H. J., Strickland, A. H., & Allan, C. A. (2013) · Bone · doi:10.1016/j.bone.2013.04.012 · Cited by 20
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
Chen, Y., Zhu, J. W., Zhou, Y., Peng, J., & Wang, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.588095 · Cited by 23
Monoclonal antibodies for the treatment of osteoporosis
Lewiecki, E. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.740006 · Cited by 21
Self-citationImpact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies
Samineni, D., Girish, S., & Li, C. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1243055 · Cited by 21
Jakovljević, A., Nikolić, N., Čarkić, J., Andrić, M., Miletić, M., Beljić-Ivanović, K., Jovanovic, T. P., & Milašin, J. (2019) · Acta Odontologica Scandinavica · doi:10.1080/00016357.2019.1658896 · Cited by 21
Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?
Henriksen, K., Bohren, K. M., Bay‐Jensen, A., & Karsdal, M. A. (2009) · Biomarkers · doi:10.3109/13547500903434519 · Cited by 20
Chiba, Y., Onouchi, T., Ikeda, T., Adachi, J., Tamura, Y., & Horiuchi, T. (2009) · Gerontology · doi:10.1159/000196280 · Cited by 23
Pathogenic bone loss in rheumatoid arthritis: mechanisms and therapeutic approaches
Cantley, M. D., Smith, M., & Haynes, D. R. (2009) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.09.42 · Cited by 22
The Role of “Bone Immunological Niche” for a New Pathogenetic Paradigm of Osteoporosis
Pagliari, D., Tamburrelli, F. C., Zirio, G., Newton, E. E., & Cianci, R. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/434389 · Cited by 30
Disorders of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent
Root, A. W., & Diamond, F. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50022-3 · Cited by 25
Denosumab for bone lesions in multiple myeloma – what is its value?
Goldstein, D. A. (2018) · Haematologica · doi:10.3324/haematol.2017.185264 · Cited by 20
Gu, J., Zhang, H., Xue, Q., Wang, L., Cheng, Z., Zhang, Y., Li, Q., Yuan, L., Li, Y., Dong, J., et al. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.06.007 · Cited by 21
Osteoclast-derived coupling factors: origins and state-of-play Louis V Avioli lecture, ASBMR 2023
Sims, N. A. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae110 · Cited by 22
Bone remodeling humoral networks and smart biomaterial technology for osteoporosis
Fini, M., Carpi, A., Borsari, V., Tschon, M., Nicolini, A., Sartori, M., Mechanick, J., & Giardino, R. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s79 · Cited by 22
Suzuki, T., Nakamura, Y., Tanaka, M., Kamimura, M., Ikegami, S., Uchiyama, S., & Kato, H. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1308454 · Cited by 19
McKee, H., Ioannidis, G., Lau, A. N., Treleaven, D. J., Gangji, A. S., Ribic, C. M., Wong‐Pack, M., Παπαϊωάννου, Α., & Adachi, J. D. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05267-1 · Cited by 19
Suppression of cancer-associated bone loss through dynamic mechanical loading
Pagnotti, G. M., Thompson, W. R., Guise, T. A., & Rubin, C. T. (2021) · Bone · doi:10.1016/j.bone.2021.115998 · Cited by 20
Pathophysiology and Clinical Manifestations of Osteoporosis
Becker, C. (2008) · Clinical cornerstone · doi:10.1016/s1098-3597(09)62038-x · Cited by 25
Characterisation of Osteoprotegerin Autoantibodies in Coeliac Disease
Real, A., Gilbert, N., Hauser, B., Kennedy, N. A., Shand, A. G., Gillett, H. R., Gillett, P. M., Goddard, C., Cebolla, Á., Sousa, C., et al. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0023-4 · Cited by 19
Adamo, V., Caristi, N., Maugeri‐Saccà, M., Ferraro, G., Arcanà, C., Maisano, R., Santini, D., & Tonini, G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1351 · Cited by 21
Tariq, M. U., Umer, M., Khan, Z., Saeed, J., Siddiqui, M. A., & Din, N. U. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151479 · Cited by 19
Lewiecki, E. M., Bilezikian, J. P., Laster, A. J., Miller, P. D., Recker, R. R., Russell, R. G. G., & Whyte, M. P. (2010) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2009.12.003 · Cited by 19
Self-citationTreatment and prevention of osteoporosis
Blahoš, J. (2007) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-007-0486-7 · Cited by 26
RANKL Links Arterial Calcification With Osteolysis
Alexander, M. Y. (2009) · Circulation Research · doi:10.1161/circresaha.109.198010 · Cited by 20
Denosumab in Postmenopausal Women with Low Bone Mineral Density
Schwartzman, J., & Yazici, Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmc060819 · Cited by 20
Hasegawa, C., & Duffull, S. B. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12324 · Cited by 18
Hu, Y., Chen, W., Lan, S., Ming, C., Xu, D., Li, H., Xu, H., Shi, D., Liu, W., Dai, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66202-z · Cited by 20
Leder, B. Z., Ramchand, S. K., Jordan, M., Ryan, S., Patnaik, A., Lee, H., & Tsai, J. N. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00319-5 · Cited by 18
How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management
Fatica, M., D’Antonio, A., Novelli, L., Triggianese, P., Conigliaro, P., Greco, E., Bergamini, A., Perricone, C., & Chimenti, M. S. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01092-4 · Cited by 19
Bone complications of androgen deprivation therapy: screening, prevention, and treatment
Lattouf, J., & Fred Saad, C. (2010) · Current Opinion in Urology · doi:10.1097/mou.0b013e32833835be · Cited by 18
Gupta, M., Shah, S., Peterson, S. J., & Baim, S. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4559-9 · Cited by 18
Should denosumab treatment for osteoporosis be continued indefinitely?
Noble, J. A., McKenna, M. J., & Crowley, R. K. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211010052 · Cited by 20
Brandi, M., & Cavalli, L. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7688 · Cited by 19
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.